Background/Aims: Dry skin, or xerosis, is a common condition and a key feature of skin diseases like atopic dermatitis (AD) and ichthyosis vulgaris. Foot xerosis may exist without underlying disease and could be related to very mild forms of AD or ichthyosis vulgaris. The synthesis of important skin lipids (cholesterol, free fatty acids and ceramides) is reduced in xerosis and AD, and reduced lipid synthesis is responsible for a lack of lipids and enzymes in the skin barrier. This slows down reorganisation of the lipid lamellae in the stratum corneum (SC). Methods: Skin barrier integrity was measured by morphometric analysis of the lipid lamellae in the SC after 4 weeks of treatment with a foam cream (active agent vs. placebo). Results: Significant treatment effects were shown after 2 and 4 weeks by an increasing amount of intercellular lipids in the SC. Conclusion: This study shows that a quick reorganisation of the SC lipids initiates a good restoration of the whole skin barrier after 4 weeks of treatment with a foam cream.

1.
Valentine J, Belum VR, Duran J, Ciccolini K, Schindler K, Wu S, Lacouture ME: Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol 2015;72:656-667.
2.
Cork JC, Danby SG, Vasilopoulus Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, MacGowan AL, Tazi-Ahnini R, Ward SJ: Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892-1908.
3.
Fartasch M: The epidermal lamellar body: a fascinating secretory organelle. J Invest Dermatol 2004;122:xi-xii.
4.
Gahli FE: Improved clinical outcomes with moisturization in dermatologic disease. Cutis 2005;76:13-18.
5.
Rehal B, Armstrong A: Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One 2011;6: e17520.
6.
Hon KL, Wang SS, Lau Z, Lee HC, Lee KKC, Leung TF, Luk MN: Pseudoceramide for childhood eczema: does it work? Hong Kong Med J 2011;17:132-136.
7.
Dähnhardt-Pfeiffer S, Surber C, Wilhelm KP, Dähnhardt D, Springmann G, Boettcher M, Foelster-Holst R: Noninvasive stratum corneum sampling and electron microscopical examination of skin barrier integrity: pilot study with a topical glycerin formulation for atopic dermatitis. Skin Pharmacol Physiol 2012;25:155-161.
8.
Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, Walter K, Proksch E, Fölster-Holst R: Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. J Dtsch Dermatol Ges 2013;4:437-443.
9.
Pinnagoda J, Tupker RA, Agner T, Serup J: Guidelines for transepidermal water loss (TEWL) measurement. Contact Dermatitis 1990;22:164-178.
10.
Berardesca E: EEMCO guidance for the assessment of stratum corneum hydration: electrical method. Skin Res Technol 1997;3:126-132.
11.
Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A: Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 1991;96:523-526.
12.
Proksch E, Lachapelle JM: The management of dry skin with topical emollients - recent perspectives. J Dtsch Dermatol Ges 2005;3:768-774.
13.
Proksch E: The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 2008;21:75-80.
14.
Weismann K, Krakauer R, Wanscher B: Prevalence of skin diseases in old age. Acta Derm Venereol 1980;60:352-353.
15.
Lodén M, von Scheele J, Michelson S: The influence of a humectant-rich mixture on normal skin barrier function and on once- and twice-daily treatment of foot xerosis. A prospective, randomized, evaluator-blind, bilateral and untreated-control study. Skin Res Technol 2013;19:438-445.
16.
Borelli C, Bielfeldt S, Borelli S, Schaller M, Korting HC: Cream or foam in pedal skin care: towards the ideal vehicle for the urea used against dry skin. Int J Cosmet Sci 2011;33:37-43.
17.
Rawlings AV, Scott IR, Harding CR, Bowser PA: Stratum corneum moisturization at the molecular level. J Invest Dermatol 1994;103:731-740.
18.
Rawlings AV, Harding CR: Moisturization and skin barrier function. Dermatol Ther 2004;17(suppl 1):43-48.
19.
Bristow I: Emollients in the care of the diabetic foot. Diabet Foot J 2013;16:63-66.
20.
Jensen JM, Pfeiffer S, Witt M, Bräutigam C, Neumann M, Weichenthal M, Schwarz T, Fölster-Holst R, Proksch E: Different effects of pimecrolimus on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009;123:1124-1133.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.